Immunic Inc (IMUX)
1.26
-0.01
(-0.79%)
USD |
NASDAQ |
May 23, 10:28
Immunic Total Assets (Quarterly): 104.16M for March 31, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 104.16M |
December 31, 2023 | 54.30M |
September 30, 2023 | 66.98M |
June 30, 2023 | 88.74M |
March 31, 2023 | 108.87M |
December 31, 2022 | 127.75M |
September 30, 2022 | 121.08M |
June 30, 2022 | 138.66M |
March 31, 2022 | 149.92M |
December 31, 2021 | 139.10M |
September 30, 2021 | 156.76M |
June 30, 2021 | 136.06M |
March 31, 2021 | 154.72M |
December 31, 2020 | 167.86M |
September 30, 2020 | 171.64M |
June 30, 2020 | 87.15M |
March 31, 2020 | 57.29M |
December 31, 2019 | 65.96M |
September 30, 2019 | 67.60M |
June 30, 2019 | 72.57M |
March 31, 2019 | 10.48M |
December 31, 2018 | 14.98M |
September 30, 2018 | 19.99M |
Date | Value |
---|---|
June 30, 2018 | 34.80M |
March 31, 2018 | 47.01M |
December 31, 2017 | 60.38M |
September 30, 2017 | 70.36M |
June 30, 2017 | 80.68M |
March 31, 2017 | 90.95M |
December 31, 2016 | 64.03M |
September 30, 2016 | 72.47M |
June 30, 2016 | 78.63M |
March 31, 2016 | 82.92M |
December 31, 2015 | 89.08M |
September 30, 2015 | 66.94M |
June 30, 2015 | 79.87M |
March 31, 2015 | 94.92M |
December 31, 2014 | 108.08M |
September 30, 2014 | 85.83M |
June 30, 2014 | 97.02M |
March 31, 2014 | 55.61M |
December 31, 2013 | 46.58M |
September 30, 2013 | 37.98M |
June 30, 2013 | 45.76M |
December 31, 2012 | 20.33M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
54.30M
Minimum
Dec 2023
171.64M
Maximum
Sep 2020
111.86M
Average
114.98M
Median
Total Assets (Quarterly) Benchmarks
Kymera Therapeutics Inc | 868.25M |
Insmed Inc | 1.159B |
SELLAS Life Sciences Group Inc | 24.43M |
Skye Bioscience Inc | 94.84M |
Leap Therapeutics Inc | 57.96M |
Total Assets (Quarterly) Related Metrics
Total Liabilities (Quarterly) | 20.58M |
Shareholders Equity (Quarterly) | 83.58M |